SG Americas Securities LLC Has $688,000 Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

SG Americas Securities LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 274.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,497 shares of the medical research company’s stock after purchasing an additional 2,564 shares during the quarter. SG Americas Securities LLC’s holdings in Charles River Laboratories International were worth $688,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Baillie Gifford & Co. acquired a new position in Charles River Laboratories International during the second quarter worth $3,380,000. Illinois Municipal Retirement Fund lifted its stake in Charles River Laboratories International by 66.7% in the second quarter. Illinois Municipal Retirement Fund now owns 5,727 shares of the medical research company’s stock valued at $1,225,000 after acquiring an additional 2,291 shares during the last quarter. Mawer Investment Management Ltd. lifted its stake in Charles River Laboratories International by 49.4% in the second quarter. Mawer Investment Management Ltd. now owns 8,923 shares of the medical research company’s stock valued at $1,909,000 after acquiring an additional 2,951 shares during the last quarter. Federated Hermes Inc. lifted its stake in Charles River Laboratories International by 9.3% in the second quarter. Federated Hermes Inc. now owns 212,868 shares of the medical research company’s stock valued at $45,547,000 after acquiring an additional 18,196 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in Charles River Laboratories International by 7.2% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 9,148 shares of the medical research company’s stock valued at $1,801,000 after acquiring an additional 613 shares during the last quarter. Institutional investors and hedge funds own 97.80% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Credit Suisse Group cut their price target on shares of Charles River Laboratories International from $285.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, November 3rd. StockNews.com began coverage on shares of Charles River Laboratories International in a research report on Wednesday, October 12th. They issued a “hold” rating on the stock. Jefferies Financial Group downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, January 12th. Morgan Stanley lowered their price target on shares of Charles River Laboratories International from $250.00 to $241.00 and set an “equal weight” rating on the stock in a report on Thursday, November 3rd. Finally, Robert W. Baird increased their price target on shares of Charles River Laboratories International from $275.00 to $285.00 and gave the company an “outperform” rating in a report on Wednesday, January 11th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of “Moderate Buy” and an average target price of $297.38.

Insider Activity at Charles River Laboratories International

In related news, CAO Michael Gunnar Knell sold 855 shares of Charles River Laboratories International stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $248.59, for a total value of $212,544.45. Following the transaction, the chief accounting officer now directly owns 6,438 shares of the company’s stock, valued at $1,600,422.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CAO Michael Gunnar Knell sold 855 shares of Charles River Laboratories International stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $248.59, for a total value of $212,544.45. Following the transaction, the chief accounting officer now directly owns 6,438 shares of the company’s stock, valued at $1,600,422.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph W. Laplume sold 6,409 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $224.25, for a total transaction of $1,437,218.25. Following the completion of the transaction, the executive vice president now directly owns 20,232 shares in the company, valued at $4,537,026. The disclosure for this sale can be found here. Insiders have sold 10,077 shares of company stock valued at $2,334,821 over the last three months. 1.10% of the stock is owned by insiders.

Charles River Laboratories International Stock Up 4.1 %

NYSE CRL opened at $243.17 on Friday. The company has a current ratio of 1.40, a quick ratio of 1.14 and a debt-to-equity ratio of 1.12. Charles River Laboratories International, Inc. has a 1-year low of $181.36 and a 1-year high of $349.84. The company has a 50 day moving average of $226.53 and a 200-day moving average of $218.49. The company has a market cap of $12.37 billion, a price-to-earnings ratio of 28.64, a PEG ratio of 1.46 and a beta of 1.29.

Charles River Laboratories International (NYSE:CRLGet Rating) last released its quarterly earnings results on Wednesday, November 2nd. The medical research company reported $2.63 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.12. Charles River Laboratories International had a net margin of 11.54% and a return on equity of 20.93%. The company had revenue of $989.16 million during the quarter, compared to the consensus estimate of $978.65 million. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 10.89 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Articles

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.